Clinical Trials Directory

Trials / Recruiting

RecruitingNCT02820233

Studies of Neuregulin/ERBB Signaling in Human Heart

Isolation and Characterization of ERBB Expressing Human Heart Progenitor Cells

Status
Recruiting
Phase
Study type
Observational
Enrollment
80 (estimated)
Sponsor
Douglas B. Sawyer · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

This study examines the role of the epidermal growth factor (EGF) receptor family and the EGF family of ligands in the regulation of non-myocytes isolated from the human heart.

Detailed description

The EGF family of receptor tyrosine kinases (a.k.a. ERBB receptors) mediate the effects of the epidermal growth factor (EGF) family including Neuregulin-1β (NRG). NRG and ERBB1-4 are critical for cardiac development and maintenance of the adult heart. Current understanding of the role of EGF/NRG/ERBB signaling in the cardiovascular system is rapidly evolving due to recent findings in non-myocyte cell populations. This study is examining a population of progenitor cells in the adult human heart that responds to EGF and NRG. Subjects are enrolled who are scheduled to undergo heart surgery and are willing to allow for a small biopsy to be taken from their hearts during surgery. Biopsies are taken to the laboratory where cells are separated and analyzed by flow cytometry and grown in cell culture to understand how their biology is regulated by NRG and EGF.

Conditions

Timeline

Start date
2015-06-01
Primary completion
2028-09-01
Completion
2029-06-01
First posted
2016-06-30
Last updated
2025-04-03

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT02820233. Inclusion in this directory is not an endorsement.